Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05617820 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,050
- Enrollment target
NCT05617820: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT05617820 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 1,050 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05617820, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,050 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
Interventions
- DRUG Placebo
- DRUG Estradiol
- DRUG Imvexxy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05617820
The ClinicalTrials.gov registry entry for NCT05617820 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05617820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05617820 about?
NCT05617820 is a clinical study titled "Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy". Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
What is the current status of trial NCT05617820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,050 participants. The study started on 2022-11-15. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT05617820?
The interventions under investigation include: Placebo (DRUG), Estradiol (DRUG), Imvexxy (DRUG).
Who is sponsoring clinical trial NCT05617820?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.